LS-HB

LS-HB is an investigational drug being developed as a photosensitizer for photodynamic therapy (PDT) in the treatment of advanced malignant tumors, including hepatocellular carcinoma. In preclinical and early clinical studies, LS-HB is administered by injection and subsequently activated by exposure to specific wavelengths of light (typically 660 nm), leading to the generation of reactive oxygen species that induce cytotoxic effects selectively in tumor cells. The drug demonstrates significant anticancer activity in vitro and in vivo when combined with light activation, with minimal toxicity observed without light exposure. The primary developer is Haining Lvsheng Medical Technology Co., Ltd., which sponsors ongoing Phase I clinical trials to evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy[3].

Other names

注射用LS-HB